268 related articles for article (PubMed ID: 30352134)
21. TP53 Germline Variations Influence the Predisposition and Prognosis of B-Cell Acute Lymphoblastic Leukemia in Children.
Qian M; Cao X; Devidas M; Yang W; Cheng C; Dai Y; Carroll A; Heerema NA; Zhang H; Moriyama T; Gastier-Foster JM; Xu H; Raetz E; Larsen E; Winick N; Bowman WP; Martin PL; Mardis ER; Fulton R; Zambetti G; Borowitz M; Wood B; Nichols KE; Carroll WL; Pui CH; Mullighan CG; Evans WE; Hunger SP; Relling MV; Loh ML; Yang JJ
J Clin Oncol; 2018 Feb; 36(6):591-599. PubMed ID: 29300620
[TBL] [Abstract][Full Text] [Related]
22. TP53 variants of uncertain significance: increasing challenges in variant interpretation and genetic counseling.
Bittar CM; Vieira IA; Sabato CS; Andreis TF; Alemar B; Artigalás O; Galvão HCR; Macedo GS; Palmero EI; Ashton-Prolla P
Fam Cancer; 2019 Oct; 18(4):451-456. PubMed ID: 31321604
[TBL] [Abstract][Full Text] [Related]
23. TP53 germline mutation testing in 180 families suspected of Li-Fraumeni syndrome: mutation detection rate and relative frequency of cancers in different familial phenotypes.
Ruijs MW; Verhoef S; Rookus MA; Pruntel R; van der Hout AH; Hogervorst FB; Kluijt I; Sijmons RH; Aalfs CM; Wagner A; Ausems MG; Hoogerbrugge N; van Asperen CJ; Gomez Garcia EB; Meijers-Heijboer H; Ten Kate LP; Menko FH; van 't Veer LJ
J Med Genet; 2010 Jun; 47(6):421-8. PubMed ID: 20522432
[TBL] [Abstract][Full Text] [Related]
24. Identification and Management of
Pal T; Brzosowicz J; Valladares A; Wiesner GL; Laronga C
South Med J; 2017 Oct; 110(10):643-648. PubMed ID: 28973705
[TBL] [Abstract][Full Text] [Related]
25. Germline TP53 Mutations in Patients With Early-Onset Colorectal Cancer in the Colon Cancer Family Registry.
Yurgelun MB; Masciari S; Joshi VA; Mercado RC; Lindor NM; Gallinger S; Hopper JL; Jenkins MA; Buchanan DD; Newcomb PA; Potter JD; Haile RW; Kucherlapati R; Syngal S;
JAMA Oncol; 2015 May; 1(2):214-21. PubMed ID: 26086041
[TBL] [Abstract][Full Text] [Related]
26. Response to: Concern regarding classification of germlineTP53 variants as likely pathogenic.
de Andrade KC; Frone MN; Wegman-Ostrosky T; Khincha PP; Kim J; Amadou A; Santiago KM; Fortes FP; Lemonnier N; Mirabello L; Stewart DR; Hainaut P; Kowalski LP; Savage SA; Achatz MI
Hum Mutat; 2019 Jun; 40(6):832-833. PubMed ID: 30997946
[No Abstract] [Full Text] [Related]
27. MIR605 rs2043556 is associated with the occurrence of multiple primary tumors in TP53 p.(Arg337His) mutation carriers.
Bandeira IC; Vieira IA; Andreis TF; Brussa Reis L; Macedo GS; Vianna FSL; Santos-Silva P; Palmero EI; Galvão HCR; Ramos CRN; Santiago KM; Achatz MI; da Costa AABA; Ashton-Prolla P
Cancer Genet; 2020 Jan; 240():54-58. PubMed ID: 31778928
[TBL] [Abstract][Full Text] [Related]
28. Biochemical and imaging surveillance in germline TP53 mutation carriers with Li-Fraumeni syndrome: 11 year follow-up of a prospective observational study.
Villani A; Shore A; Wasserman JD; Stephens D; Kim RH; Druker H; Gallinger B; Naumer A; Kohlmann W; Novokmet A; Tabori U; Tijerin M; Greer ML; Finlay JL; Schiffman JD; Malkin D
Lancet Oncol; 2016 Sep; 17(9):1295-305. PubMed ID: 27501770
[TBL] [Abstract][Full Text] [Related]
29. TP53 germline and somatic mutations in a patient with fibrolamellar hepatocellular carcinoma.
Andrade RC; de Lima MAFD; de Faria PAS; Vargas FR
Fam Cancer; 2018 Jan; 17(1):119-122. PubMed ID: 28477317
[TBL] [Abstract][Full Text] [Related]
30. A novel TP53 germline inframe deletion identified in a Spanish series of Li-fraumeni syndrome suspected families.
Llovet P; Illana FJ; Martín-Morales L; de la Hoya M; Garre P; Ibañez-Royo MD; Pérez-Segura P; Caldés T; García-Barberán V
Fam Cancer; 2017 Oct; 16(4):567-575. PubMed ID: 28573494
[TBL] [Abstract][Full Text] [Related]
31. Prevalence of low-penetrant germline TP53 D49H mutation in Japanese cancer patients.
Yamaguchi K; Urakami K; Nagashima T; Shimoda Y; Ohnami S; Ohnami S; Ohshima K; Mochizuki T; Hatakeyama K; Serizawa M; Akiyama Y; Maruyama K; Katagiri H; Ishida Y; Takahashi K; Nishimura S; Terashima M; Kawamura T; Kinugasa Y; Yamakawa Y; Onitsuka T; Ohde Y; Sugino T; Ito I; Matsubayashi H; Horiuchi Y; Mizuguchi M; Yamazaki M; Inoue K; Wakamatsu K; Sugiyama M; Uesaka K; Kusuhara M
Biomed Res; 2016; 37(4):259-64. PubMed ID: 27545002
[TBL] [Abstract][Full Text] [Related]
32. Pediatric oncologist willingness to offer germline TP53 testing in osteosarcoma.
Shaul E; Roth M; Lo Y; Geller DS; Hoang B; Yang R; Malkin D; Gorlick R; Gill J
Cancer; 2018 Mar; 124(6):1242-1250. PubMed ID: 29313943
[TBL] [Abstract][Full Text] [Related]
33. Evaluation of TP53 Pro72Arg and MDM2 SNP285-SNP309 polymorphisms in an Italian cohort of LFS suggestive patients lacking identifiable TP53 germline mutations.
Ponti F; Corsini S; Gnoli M; Pedrini E; Mordenti M; Sangiorgi L
Fam Cancer; 2016 Oct; 15(4):635-43. PubMed ID: 26956143
[TBL] [Abstract][Full Text] [Related]
34. Super-Transactivation TP53 Variant in the Germline of a Family with Li-Fraumeni Syndrome.
Id Said B; Kim H; Tran J; Novokmet A; Malkin D
Hum Mutat; 2016 Sep; 37(9):889-92. PubMed ID: 27297285
[TBL] [Abstract][Full Text] [Related]
35. The TP53 gene promoter is not methylated in families suggestive of Li-Fraumeni syndrome with no germline TP53 mutations.
Finkova A; Vazna A; Hrachovina O; Bendova S; Prochazkova K; Sedlacek Z
Cancer Genet Cytogenet; 2009 Aug; 193(1):63-6. PubMed ID: 19602465
[TBL] [Abstract][Full Text] [Related]
36. Clinical spectrum of Li-Fraumeni syndrome/Li-Fraumeni-like syndrome in Brazilian individuals with the TP53 p.R337H mutation.
Ferreira AM; Brondani VB; Helena VP; Charchar HLS; Zerbini MCN; Leite LAS; Hoff AO; Latronico AC; Mendonca BB; Diz MDPE; de Almeida MQ; Fragoso MCBV
J Steroid Biochem Mol Biol; 2019 Jun; 190():250-255. PubMed ID: 30974190
[TBL] [Abstract][Full Text] [Related]
37. Li-Fraumeni and related syndromes: correlation between tumor type, family structure, and TP53 genotype.
Olivier M; Goldgar DE; Sodha N; Ohgaki H; Kleihues P; Hainaut P; Eeles RA
Cancer Res; 2003 Oct; 63(20):6643-50. PubMed ID: 14583457
[TBL] [Abstract][Full Text] [Related]
38. From uncertainty to pathogenicity: clinical and functional interrogation of a rare
Quinn EA; Maciaszek JL; Pinto EM; Phillips AH; Berdy D; Khandwala M; Upadhyaya SA; Zambetti GP; Kriwacki RW; Ellison DW; Nichols KE; Kesserwan C
Cold Spring Harb Mol Case Stud; 2019 Aug; 5(4):. PubMed ID: 30886117
[TBL] [Abstract][Full Text] [Related]
39. Germline TP53 variants and susceptibility to osteosarcoma.
Mirabello L; Yeager M; Mai PL; Gastier-Foster JM; Gorlick R; Khanna C; Patiño-Garcia A; Sierrasesúmaga L; Lecanda F; Andrulis IL; Wunder JS; Gokgoz N; Barkauskas DA; Zhang X; Vogt A; Jones K; Boland JF; Chanock SJ; Savage SA
J Natl Cancer Inst; 2015 Jul; 107(7):. PubMed ID: 25896519
[TBL] [Abstract][Full Text] [Related]
40. Germline TP53 mutations and Li-Fraumeni syndrome.
Varley JM
Hum Mutat; 2003 Mar; 21(3):313-20. PubMed ID: 12619118
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
